Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?

Z. Layegh; F. Hooijberg; C. Bastida; A. D.R. Huitema; T. Rispens; C. G. Wolbink

doi:10.55563/CLINEXPRHEUMATOL/XN5I2Y

Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?

Z. Layegh, F. Hooijberg, C. Bastida, A. D.R. Huitema, T. Rispens, C. G. Wolbink

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

1 Citaat (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	664-665
Aantal pagina's	2
Tijdschrift	Clinical and experimental rheumatology
Volume	40
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.55563/CLINEXPRHEUMATOL/XN5I2Y
Status	Gepubliceerd - 2022
Extern gepubliceerd	Ja

Toegang tot document

10.55563/CLINEXPRHEUMATOL/XN5I2Y

Citeer dit

@article{1eeb16de425d4c64aa25b0a83c9468b8,

title = "Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?",

author = "Z. Layegh and F. Hooijberg and C. Bastida and Huitema, {A. D.R.} and T. Rispens and Wolbink, {C. G.}",

year = "2022",

doi = "10.55563/CLINEXPRHEUMATOL/XN5I2Y",

language = "English",

volume = "40",

pages = "664--665",

journal = "Clinical and experimental rheumatology",

issn = "0392-856X",